HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

David Vs Goliath – Flarin’s Macmillen On Slugging It Out With The Heavyweights

Executive Summary

HBW Insight Exclusive: Flarin boss Andrew Macmillen on competing with the big OTC incumbents as a lean, innovation-focused company.

You may also be interested in...



EU Business Round-Up: Mayoly Spindler Acquires Biohealth, Flarin Gets Funding, Karo Ready For M&A

The latest European consumer health business news: France's Mayoly Spindler acquires Italian supplements specialist Biohealth; UK-based Flarin gets funding to expand at home and abroad; and Sweden's Karo plots further M&A in 2021.

Top 10 UK OTC Marketing Stories 2020: Digital Health And Probiotics Lead The Way

HBW Insight's countdown of the top-10 most read UK OTC marketing stories in 2020 includes launches and campaigns from consumer health players such as Sanofi, J&J, GSK and Bayer, amongst others.

‘Meaningful Revenues’ In 2023 Mark Strategic Milestone As Futura Looks To Future

Futura recorded its first notable revenues last year, generated by the launch of its Eroxon erectile dysfunction gel in the UK and Europe, marking the company's transition from an R&D startup to a consumer healthcare player in its own right. To mark the occasion, CEO James Barder outlines a new strategy, with a focus on innovation in sexual wellness, further global partnerships and sustained profitability. 

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS150050

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel